StockData
AVITA Medical, Inc. logo

AVITA Medical, Inc. (RCEL) stock

RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$17.30−0.35 (-1.98%)

Close on Nov 11, 2026Market cap $535.03MP/E –Yield –

AVITA Medical, Inc. grew revenue 17.0% to $84.68M over the twelve months to Sep 30, 2026. Free cash flow was -$19.29M. At the latest close the market valued the company at $535.03M.

Revenue
$84.68M
+17.0% vs. a year earlier
Operating income
-$28.70M
TTM Q3 2026
Free cash flow
-$19.29M
TTM Q3 2026
EPS, diluted
-$1.18
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$535.03M
P/E ratio
–
Price to sales
6.32
Price to book
–
Dividend yield
–
Free cash flow yield
-3.60%

Fundamentals

Revenue
$84.68M
Net income
-$36.12M
EPS, diluted
-$1.18
Free cash flow
-$19.29M
Book value per share
-$1.01
Diluted shares
31M

Trading

Next earnings
Feb 11, 2027 (estimated, during market hours)
Previous close
$17.65
Open
$17.65
Day's range
$17.12 – $18.24
Volume
674,543
Average volume (20 days)
570,021
Beta (5 years)
1.99
52-week range
$3.22 – $18.43
RSI (14 days)
68.0
Volatility (1 year)
94.6%
Relative volume
1.47×
WACC
14.4%

Market cap history

Month-end market cap since 2017, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

PeriodRCELS&P 500DifferenceRCEL per yearS&P 500 per year
1 month+31.0%-2.4%+33.4 pts
3 months+111.0%-1.2%+112.1 pts
Year to date+401.4%+12.3%+389.2 pts
1 year+336.9%+12.4%+324.4 pts
3 years+53.2%+78.8%−25.6 pts+15.3%+21.4%
5 years+4.5%+75.2%−70.7 pts+0.9%+11.9%
10 years+70.4%+311.1%−240.7 pts+5.5%+15.2%

Eight years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Revenue

$84.68M+17.0% YoY

Gross profit

$69.75M+15.0% YoY

Operating income

-$28.70M

Net income

-$36.12M

EPS, diluted

-$1.18

Free cash flow

-$19.29M
Reported periodTrailing twelve months

Press releases

Releases AVITA Medical filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About AVITA Medical

Surgical & Medical Instruments & Apparatus

AVITA Medical is a medical technology company that develops and commercializes regenerative therapeutics for acute wound care. Its primary product is the RECELL system, a point-of-care autologous cell harvesting device that processes a small donor skin sample into a cellular suspension to treat thermal burns and full-thickness skin defects. The company also offers PermeaDerm, a biosynthetic wound matrix that provides protective coverage, and Cohealyx, a collagen-based dermal matrix designed for wound bed preparation. Its commercial products primarily serve surgeons, clinicians, acute care hospitals, specialized burn centers, and trauma centers treating complex surgical and traumatic injuries.

Company profile, executives and history

AVITA Medical stock: common questions

What is AVITA Medical's stock price?

RCEL closed at $17.30 on Nov 11, 2026, down 1.98% on the day. Over the past 52 weeks it traded between $3.22 and $18.43.

What is AVITA Medical's market cap?

AVITA Medical was worth $535.03M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.

What is RCEL's P/E ratio?

AVITA Medical lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.18), so it has no meaningful P/E ratio.

How much revenue does AVITA Medical make?

AVITA Medical reported revenue of $84.68M for the twelve months to Sep 30, 2026, up 17.0% from a year earlier.

Does AVITA Medical pay a dividend?

No. AVITA Medical has not paid a cash dividend over the last twelve months.

When does AVITA Medical report earnings next?

AVITA Medical is expected to report Q4 FY2026 results on Feb 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.

How has RCEL stock performed over the past year?

Including dividends, RCEL returned +336.9% over the past year, against +12.4% for the S&P 500.

Who are AVITA Medical's competitors?

Companies most similar to AVITA Medical by business, industry and size include TELA, APYX, MDXG, PDEX, SNWV.

See a number that looks wrong?